Short-term Efficacy and Safety of Tolvaptan for the Refractory Heart Failure of the Elderly Patients

2012 ◽  
Vol 18 (10) ◽  
pp. S181
Author(s):  
Hajime Fujimoto ◽  
Kazumasa Harada
Keyword(s):  
Heart Failure ◽  
Elderly Patients ◽  
The Elderly ◽  
Efficacy And Safety ◽  
Short Term ◽  
Term Efficacy ◽  
Refractory Heart Failure

The Short-term Efficacy and Safety of Tolvaptan for the Heart Failure Patients with Resistance to Diuretics

2012 ◽  
Vol 18 (10) ◽  
pp. S174
Author(s):  
Satoshi Koizumi ◽  
Reiko Fukuda ◽  
Nobuo Koshiji ◽  
Akiko Haruyama ◽  
Yuu Nishi ◽  
...  
Keyword(s):  
Heart Failure ◽  
Efficacy And Safety ◽  
Short Term ◽  
Heart Failure Patients ◽  
Term Efficacy ◽  
Resistance To Diuretics

scholarly journals Short-term efficacy and safety of levosimendan in patients with chronic systolic heart failure

2020 ◽  
Vol 31 (4) ◽  
pp. 34-38
Author(s):  
Xiao-Ran Cui ◽  
Xiao-Hong Yang ◽  
Rui-Bin Li ◽  
Dong Wang ◽  
Min Jia ◽  
...  
Keyword(s):  
Heart Failure ◽  
Systolic Heart Failure ◽  
Efficacy And Safety ◽  
Short Term ◽  
Term Efficacy ◽  
Chronic Systolic Heart Failure

Short‐Term Efficacy and Safety of Extended‐Release Fluvastatin in a Large Cohort of Elderly Patients

2003 ◽  
Vol 12 (4) ◽  
pp. 225-231 ◽  
Author(s):  
Eric Bruckert ◽  
Michel Lièvre ◽  
Philippe Giral ◽  
Gaetano Crepaldi ◽  
Luis Masana ◽  
...  
Keyword(s):  
Elderly Patients ◽  
Extended Release ◽  
Large Cohort ◽  
Efficacy And Safety ◽  
Short Term ◽  
Term Efficacy

scholarly journals Short-term efficacy and safety of antithymocyte globulin treatment in elderly patients with acquired aplastic anaemia

2016 ◽  
Vol 180 (3) ◽  
pp. 459-462 ◽  
Author(s):  
Jennifer M-L. Tjon ◽  
Marco R. de Groot ◽  
Saskia M.A. Sypkens Smit ◽  
Liesbeth C. de Wreede ◽  
Tjeerd J.F. Snijders ◽  
...  
Keyword(s):  
Elderly Patients ◽  
Aplastic Anaemia ◽  
Antithymocyte Globulin ◽  
Efficacy And Safety ◽  
Short Term ◽  
Term Efficacy

106 Precipitating factors in the elderly patients admitted with the diagnosis of heart failure. Are easy to find?

2006 ◽  
Vol 5 (1) ◽  
pp. 25-26
Author(s):  
R VIDALPEREZ ◽  
E ABUASSI ◽  
M PARAMODEVEGA ◽  
P VELOSO ◽  
A VARELAROMAN ◽  
...  
Keyword(s):  
Heart Failure ◽  
Elderly Patients ◽  
The Elderly ◽  
Precipitating Factors

Long-term efficacy and safety of imiquimod 5% and fluorouracil 1% creams in medical monotherapy of complex eyelid basal cell carcinomas

2021 ◽  
pp. 112067212110356
Author(s):  
Manpreet Singh ◽  
Aditi Mehta Grewal ◽  
Himanshi Singh ◽  
Manjula Sharma ◽  
Manpreet Kaur ◽  
...  
Keyword(s):  
Basal Cell ◽  
Side Effect ◽  
The Elderly ◽  
Fixed Dose ◽  
Side Effect Profile ◽  
Efficacy And Safety ◽  
Term Efficacy ◽  
Basal Cell Carcinomas ◽  
Double Blinded

Purpose: To study the long-term efficacy and safety of local application of imiquimod 5% and fluorouracil 1% creams in complex eyelid basal cell carcinomas (BCCs). Methods: A retrospective, non-comparative study in biopsy-proven, complex (involving canthi or >50% of eyelid length) eyelid BCC patients who were medically unfit for surgical procedures. All patients were medically treated with either of the creams using fixed-dose regimens for a minimum of 3 months. All received oral vitamin C 500 mg QID for 3 months as an adjunct for collagen healing. A minimum of “post-treatment” follow-up of 12 months was observed. Results: Of total 30 patients, imiquimod 5% and fluorouracil 1% were used in 16 and 14 patients, respectively. The mean age of our patients was 70.5 years. The co-morbidities included – severe coronary artery disease using blood-thinners ( n = 19), poorly controlled diabetes ( n = 12), poorly controlled hypertension ( n = 6), on nebulization ( n = 3), and tuberculosis with pulmonary fibrosis ( n = 2). Complete clinical tumor resolution was noted in 10 and 8 patients over 12 and 16.5 weeks, respectively, in imiquimod and fluorouracil groups. Periocular skin erythema, chemical conjunctivitis, and skin depigmentation were seen in all the patients of imiquimod group. On the other hand, the local side-effect profile in fluorouracil patients was limited. Conclusion: The medical treatment of complex eyelid BCC is a useful alternative to surgery in the elderly with significant co-morbidities. It provides a promising long-term relief with a tolerable side-effect profile. A prospective, randomized, double-blinded trial would provide stronger evidence for the efficacy of these drugs.

Thiamine level in the elderly patients with heart failure

2004 ◽  
Vol 10 (5) ◽  
pp. S172
Author(s):  
Terada Hajime ◽  
Katoh Hideki ◽  
Satoh Hiroshi ◽  
Hayashi Hideharu
Keyword(s):  
Heart Failure ◽  
Elderly Patients ◽  
The Elderly ◽  
Patients With Heart Failure ◽  
Thiamine Level

scholarly journals Целевой уровень артериального давления при лечении артериальной гипертензии у пациентов пожилого возраста с хронической сердечной недостаточностью

2019 ◽  
pp. 8-16
Author(s):  
M.S. CHERNIAEVA ◽  
O.D. OSTROUMOVA
Keyword(s):  
Heart Failure ◽  
Blood Pressure ◽  
Ejection Fraction ◽  
Elderly Patients ◽  
Cardiovascular Events ◽  
The Elderly ◽  
Target Blood Pressure ◽  
Lower Systolic Blood Pressure ◽  
Reduced Ejection Fraction ◽  
Increased Risk

Высокая распространенность хронической сердечной недостаточности (ХСН) в популяции пожилых пациентов наряду с устойчивым ро- стом численности пожилого населения как в России, так и в западных странах все больше привлекает внимание врачей к проблеме, связан- ной с ведением данного заболевания. Известно, что ведущим фактором риска развития ХСН является повышенное артериальное давление (АД) и большинство пациентов с ХСН имеют в анамнезе артериальную гипертонию (АГ), поэтому лечение пациентов пожилого возраста c АГ и ХСН является одним из важных направлений в профилактике прогрессирования ХСН, снижения количества госпитализаций и смерт- ности. Лечение АГ у пожилых имеет свои особенности, связанные с функциональным статусом пациентов и их способностью переносить лечение. В европейских рекомендациях (2018) пересмотрены целевые цифры АД при лечении АГ у пожилых, однако данные по целевым цифрам АД для лечения АГ у пациентов с ХСН опираются лишь на исследования, проводившиеся у больных без ХСН. Данные об оптималь- ном целевом уровне у пациентов с АГ и ХСН представлены в единичных исследованиях. В настоящей статье проанализирована взаимосвязь уровня АД и сердечно-сосудистых событий и смертности отдельно для пациентов с АГ и сердечной недостаточностью с низкой фракцией выброса левого желудочка и с сохраненной фракцией выброса левого желудочка. Результаты многих исследований показывают, что более низкий уровень систолического АД (120 мм рт. ст.) и диастолического АД (80 мм рт. ст.) ассоциирован с развитием неблагоприятных сердечно-сосудистых событий, особенно у пациентов с сердечной недостаточностью с низкой фракцией выброса левого желудочка.The high prevalence of chronic heart failure (CHF) in the elderly patients, along with the steady growth of the elderly population, both in Russia and in Western countries, is increasingly attracting the attention of doctors to the problem associated with the management of this disease. It is known that the leading risk factor for CHF is high blood pressure (BP) and most patients with CHF have a history of hypertension (H), so the treatment of elderly patients with H and CHF is the major focus in the slowing CHF progression, reducing the heart failure hospitalisation and mortality. Treatment of hypertension in the elderly has some specific features associated with the functional status of patients and their ability to tolerate treatment. The European recommendations (2018) revised target blood pressure levels in the elderly patients, however, data on target blood pressure levels in patients with CHF are based only on studies conducted in patients without CHF, data on the optimal target blood pressure levels in patients with hypertension and CHF are presented in single studies. In this article we analyze the relationship between blood pressure levels and cardiovascular events and mortality separately for patients with hypertension and heart failure with reduced ejection fraction and with preserved ejection fraction. Several studies show that lower systolic blood pressure (120 mm Hg) and diastolic blood pressure (80 mm Hg) is associated with the increased risk of cardiovascular events, especially in patients with heart failure with reduced ejection fraction.

Sign in / Sign up

Export Citation Format

Share Document